Open Orphan PLC Positive in vitro results for FLU-v published
September 30 2022 - 1:00AM
RNS Non-Regulatory
TIDMORPH
Open Orphan PLC
30 September 2022
Open Orphan plc
("Open Orphan" or the "Company")
Positive in vitro results for FLU-v published in Vaccines
Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO)
effective 26 October 2022), a rapidly growing specialist contract
research organisation (CRO) and world leader in testing infectious
and respiratory disease products using human challenge clinical
trials, announces that positive data from a peer-reviewed study
evaluating the in vitro efficacy of FLU-v, Imutex Limited's
("Imutex") broad spectrum influenza vaccine, has been published in
the scientific journal Vaccines.(1)
Previous clinical studies have demonstrated that FLU-v induced
increased antibody and cellular responses in vivo. This
placebo-controlled study evaluated the ability of FLU-v to induce
cellular effector functions and cross-reactivity (both measures of
the immune response, with cross-reactivity being particularly
important for protection against multiple viral strains) of immune
cells extracted from participants, following exposure to five
different influenza strains.
The study found that measurements of IFN-<GAMMA> and
granzyme B production in stimulated immune cells from participants
that had been previously vaccinated with either FLU-v or placebo,
were significantly higher in the FLU-v group both when stimulated
with vaccine antigen and also with antigens from a panel of
seasonal and pandemic inactivated influenza A and B strains. These
results further support the continued development of FLU-v as a
broad-spectrum influenza vaccine.
FLU-v is owned by Imutex, a joint venture between hVIVO and
PepTcell Limited (the legal name of SEEK Group) , to develop
vaccines against influenza and mosquito borne diseases such as Zika
virus, malaria and other flaviviruses.
Seasonal influenza causes significant morbidity and mortality
each year and a pandemic influenza continues to pose a worldwide
threat. Influenza is a serious global health threat with an
estimated 1 billion cases per year, 3-5 million severe cases and
290,000 - 650,000 deaths per year.
Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, said :
"It is encouraging to see further positive data for FLU-v,
supporting its continued development as a broad-spectrum influenza
vaccine. There is a large unmet need for a broad-spectrum vaccine
to help battle emerging seasonal and pandemic influenza A and B
viruses. Although FLU-v had already produced successful Phase II
clinical data, this in vitro study is particularly important as it
showed the ability of the candidate to induce an immune response
against a diverse variety of influenza A and B strains."
(1.) Oftung, F.; Næss, L.M.; Laake, I.; Stoloff, G.;
Pleguezuelos, O. FLU-v, a Broad-Spectrum Influenza Vaccine, Induces
Cross-Reactive Cellular Immune Responses in Humans Measured by Dual
IFN-<GAMMA> and Granzyme B ELISpot Assay. Vaccines 2022, 10,
1528. https://doi.org/10.3390/vaccines10091528
For further information please contact:
Open Orphan plc +44 (0) 20 7756 1300
Yamin Khan, Chief Executive Officer
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780 or openorphan@walbrookpr.com
Stephanie Cuthbert / Phillip Marriage / +44 (0) 7796 794 663 / +44 (0) 7867 984 082 /
Louis Ashe-Jepson +44 (0) 7747 515 393
Notes to Editors
Open Orphan plc (London and Euronext: ORPH) is changing its name
to hVIVO plc (AIM and Euronext: HVO), which is expected to take
effect on the AIM market of the London Stock Exchange and the
Euronext Growth Exchange market on 26 October 2022.
hVIVO is a rapidly growing contract research company that is a
world leader in testing infectious and respiratory disease products
using human challenge clinical trials. The Company provides
services to Big Pharma, biotech, and government/public health
organisations.
The Company has a leading portfolio of human challenge study
models for infectious and respiratory diseases and is developing a
number of new models, such as malaria and COVID-19, to address the
dramatic growth of the global infectious disease market. The Paris
and Breda offices have over 25 years of experience providing drug
development services such as biometry, data management, statistics
CMC, PK and medical writing to third party clients as well as
supporting the London-based challenge studies.
hVIVO runs challenge studies in London from its Whitechapel
quarantine clinic, its state-of-the-art QMB clinic with its highly
specialised on-site virology and immunology laboratory, and its
newly opened clinic in Plumbers Row. To recruit volunteers /
patients for its studies, the Company leverages its unique clinical
trial recruitment capacity via its FluCamp volunteer screening
facilities in London and Manchester. The newly opened facilities
have expanded the scope of the business to enable the offering of
Phase I and Phase II vaccine field trials, PK studies, bridging
studies, and patient trials as part of large international
multi-centre studies.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRALLMATMTITBJT
(END) Dow Jones Newswires
September 30, 2022 02:00 ET (06:00 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Feb 2025 to Mar 2025
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Mar 2024 to Mar 2025
